CN104529945A - 使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法 - Google Patents

使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法 Download PDF

Info

Publication number
CN104529945A
CN104529945A CN201410513670.3A CN201410513670A CN104529945A CN 104529945 A CN104529945 A CN 104529945A CN 201410513670 A CN201410513670 A CN 201410513670A CN 104529945 A CN104529945 A CN 104529945A
Authority
CN
China
Prior art keywords
compound
disease
ret
injury
gdnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410513670.3A
Other languages
English (en)
Chinese (zh)
Inventor
M.萨尔玛
M.卡雷尔森
M.贝斯帕罗夫
M.皮尔夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GeneCode AS
Original Assignee
GeneCode AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GeneCode AS filed Critical GeneCode AS
Publication of CN104529945A publication Critical patent/CN104529945A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
CN201410513670.3A 2009-12-11 2010-12-13 使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法 Pending CN104529945A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28585809P 2009-12-11 2009-12-11
US61/285,858 2009-12-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2010800637467A Division CN103180297A (zh) 2009-12-11 2010-12-13 使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法

Publications (1)

Publication Number Publication Date
CN104529945A true CN104529945A (zh) 2015-04-22

Family

ID=43502911

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410513670.3A Pending CN104529945A (zh) 2009-12-11 2010-12-13 使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法
CN2010800637467A Pending CN103180297A (zh) 2009-12-11 2010-12-13 使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010800637467A Pending CN103180297A (zh) 2009-12-11 2010-12-13 使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法

Country Status (9)

Country Link
US (1) US8901129B2 (enExample)
EP (1) EP2509953B1 (enExample)
JP (1) JP2013513588A (enExample)
CN (2) CN104529945A (enExample)
AU (1) AU2010329847A1 (enExample)
BR (1) BR112012014022A2 (enExample)
CA (1) CA2783934A1 (enExample)
MX (1) MX2012006580A (enExample)
WO (1) WO2011070177A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110167558A (zh) * 2016-12-21 2019-08-23 阿泽克制药公司 三嗪三酮衍生物及其作为神经营养素受体和受体酪氨酸激酶的调节剂的用途

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014041179A1 (en) * 2012-09-17 2014-03-20 Chemedest Ltd. Treatment of peripheral neuropathy using gfr(alpha)3 type receptor agonists
CN103146798B (zh) * 2013-02-25 2015-04-08 潍坊易思特生物科技有限公司 一种测定重组人胶质细胞源性神经营养因子活性的细胞学方法
CN105640955B (zh) * 2016-01-28 2019-12-24 昆明医科大学 一种Aminoquinol的新用途
CN105906608B (zh) * 2016-05-03 2018-10-19 中山大学 8-氨基喹啉-松果体素杂联体及其药物组合物
JP7000349B2 (ja) * 2016-05-13 2022-02-04 インスティテュート デ メディシナ モレキュラー ジョアオ ロボ アントゥネス Ｉｌｃ３細胞に関連する疾患を処置する方法
CN107337641B (zh) * 2017-07-01 2020-04-28 广东医科大学 一种4-柔性胺基-2-芳乙烯基喹啉类衍生物及其制备方法和应用
BR112023020152A2 (pt) 2021-03-31 2023-11-14 Cambridge Entpr Ltd Inibidores terapêuticos de sinalização gdf15
JP2024522938A (ja) 2021-06-03 2024-06-21 フンダサン デー．アンナ ジ ソーメル チャンパリマウド エー ドクトル カルロス モンテス チャンパリマウド 脳－脂肪回路を介してｉｌｃ２および肥満度を制御する神経－間葉単位
AU2022387671B2 (en) 2021-11-12 2024-11-07 Axent Biosciences Inc. Methods for production of functional neurons
KR20250044337A (ko) 2022-07-28 2025-03-31 제네코드 신규의 설폰아마이드 및 신경보호제 및/또는 신경회복제로서의 이의 용도
JP2025525081A (ja) * 2022-07-28 2025-08-01 ジーンコード 新規スルホン並びに神経保護剤及び／又は神経修復剤としてのその使用
WO2024079351A1 (en) 2022-10-14 2024-04-18 Genecode Novel piperazine-based sulfonamides and their use as neuroprotective and/or neurorestorative agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225076A1 (en) * 2000-03-15 2003-12-04 Cathlin Biwersi 5-Amide substituted diarylamines as mex inhibitors
US20040034019A1 (en) * 2002-08-08 2004-02-19 Ronald Tomlinson Piperazine and piperidine derivatives
WO2006094843A1 (en) * 2005-03-11 2006-09-14 Glaxo Group Limited Piperazine derivatives as glyt1 inhibitors

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2531011A (en) * 1949-01-22 1950-11-21 Sterling Drug Inc 3-chloro-9-[2-(2-hydroxyethylamino)-ethylamino] acridine and method for its production
US3232945A (en) 1962-08-13 1966-02-01 S E Massengill Company 7,8,9,10-tetrahalo-6h-cyclohepta-(b)-quinolines
US3458525A (en) * 1966-07-01 1969-07-29 American Home Prod Spiro(indoline-3,2'-thiazolidine)-2-one and derivatives
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
EP0268871A1 (en) * 1986-10-31 1988-06-01 Sumitomo Pharmaceuticals Company, Limited Quinoline derivatives
WO1988007852A1 (en) 1987-04-06 1988-10-20 Innovative Therapeutics Corporation Liposome entrapped magnesium
WO1988007851A1 (en) 1987-04-06 1988-10-20 Innovative Therapeutics Corporation Liposome entrapped n-methyl-d-aspartate receptor blockers
US5284876A (en) 1988-02-26 1994-02-08 Neuromedica, Inc. Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents
US4939174A (en) 1988-02-26 1990-07-03 Shashoua Victor E Appetite suppression with dopamine-fatty acid conjugates
US4933324A (en) 1988-02-26 1990-06-12 Shashoua Victor E Fatty acid-neuroactive drug conjugate as a prodrug
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5227170A (en) 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US4999430A (en) * 1989-07-31 1991-03-12 Warner-Lambert Company Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine
US5182107A (en) 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
WO1991004014A1 (en) 1989-09-21 1991-04-04 Synergen, Inc. Method for transporting compositions across the blood brain barrier
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5527528A (en) 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
CA2029497C (en) * 1989-11-08 2002-06-04 Kunihiro Ninomiya (Deceased) 4-acylaminopyridine derivative
JPH03236315A (ja) 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5109921A (en) 1991-04-29 1992-05-05 Halliburton Company Controlled weak point for wireline cable
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US5260308A (en) 1991-11-06 1993-11-09 Mayo Foundation For Medical Education And Research Method to increase permeability of the blood-nerve/brain barriers to proteins
JPH07509444A (ja) 1991-11-26 1995-10-19 アルカーメス・インコーポレーテツド トランスフェリンセレプター特異的抗体−神経薬又は診断薬複合体の製造法
AU668384B2 (en) 1992-03-12 1996-05-02 Alkermes Controlled Therapeutics, Inc. Controlled release ACTH containing microspheres
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
US5583020A (en) 1992-11-24 1996-12-10 Ribozyme Pharmaceuticals, Inc. Permeability enhancers for negatively charged polynucleotides
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5462854A (en) 1993-04-19 1995-10-31 Beckman Instruments, Inc. Inverse linkage oligonucleotides for chemical and enzymatic processes
US5534259A (en) 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
ATE321882T1 (de) 1997-07-01 2006-04-15 Isis Pharmaceuticals Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
US6235769B1 (en) 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
EP1156812A4 (en) 1999-02-23 2004-09-29 Isis Pharmaceuticals Inc MULTIPARTICULAR FORMULATION
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
FI20000480A0 (fi) * 2000-03-01 2000-03-01 Orion Yhtymae Oyj Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
JP2006514917A (ja) * 2002-07-09 2006-05-18 アルファ リサーチ グループ， エルエルシー パーキンソン病および遅発性ジスキネジーの処置のための組成物および方法
AU2003263518A1 (en) 2002-10-09 2004-05-04 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
US20060281803A1 (en) * 2003-09-23 2006-12-14 Lindsley Craig W Pyrazole modulators of metabotropic glutamate receptors
WO2005113523A1 (en) 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
AU2006218405A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Acridine and quinoline derivatives as sirtuin modulators
DE202005008426U1 (de) 2005-05-31 2005-09-15 Ricon Sieb Und Foerdertechnik Fördervorrichtung mit Fördertuch
JP5388574B2 (ja) * 2005-05-31 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なヘテロ環式類
EP2526942B1 (en) 2005-06-08 2017-08-09 The University of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
WO2008010984A2 (en) * 2006-07-17 2008-01-24 The Trustees Of The University Of Pennsylvania Acridine activation of p53 and uses thereof
US7605265B2 (en) * 2007-01-22 2009-10-20 Biotechnology Research Corporation Ltd. Heterodimers and methods of using them
US20080234267A1 (en) * 2007-03-20 2008-09-25 Karen Elizabeth Lackey Compounds and Methods of Treatment
CN101784533B (zh) 2007-08-22 2013-08-21 艾博特股份有限两合公司 4-苄基氨基喹啉、含有它们的药物组合物和它们在治疗中的用途
US7863295B2 (en) * 2008-02-12 2011-01-04 Children's Medical Center Corporation Treatments for neuropathy
US20110045100A1 (en) 2008-03-05 2011-02-24 Georgetown University Antimalarial Quinolines and Methods of Use Thereof
US10867398B2 (en) 2017-11-21 2020-12-15 Reliance Core Consulting LLC Methods, systems, apparatuses and devices for facilitating motion analysis in an environment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225076A1 (en) * 2000-03-15 2003-12-04 Cathlin Biwersi 5-Amide substituted diarylamines as mex inhibitors
US20040034019A1 (en) * 2002-08-08 2004-02-19 Ronald Tomlinson Piperazine and piperidine derivatives
WO2006094843A1 (en) * 2005-03-11 2006-09-14 Glaxo Group Limited Piperazine derivatives as glyt1 inhibitors

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
-: "RN 924537-98-4", 《STN REGISTRY》, 2 March 2007 (2007-03-02) *
-: "RN 924539-62-8", 《STN REGISTRY》, 2 March 2007 (2007-03-02) *
-: "RN 924551-57-5", 《STN REGISTRY》, 2 March 2007 (2007-03-02) *
-: "RN 924553-86-6", 《STN REGISTRY》, 2 March 2007 (2007-03-02) *
-: "RN 924564-95-4", 《STN REGISTRY》, 2 March 2007 (2007-03-02) *
-: "RN 924576-91-0", 《STN REGISTRY》, 2 March 2007 (2007-03-02) *
-: "RN 924577-01-5", 《STN REGISTRY》, 2 March 2007 (2007-03-02) *
-: "RN 924730-35-8", 《STN REGISTRY》, 5 March 2007 (2007-03-05) *
-: "RN 924740-23-8", 《STN REGISTRY》, 5 March 2007 (2007-03-05) *
-: "RN 924756-06-9", 《STN REGISTRY》, 5 March 2007 (2007-03-05) *
-: "RN 924759-42-2", 《STN REGISTRY》, 5 March 2007 (2007-03-05) *
-: "RN 924762-99-2", 《STN REGISTRY》, 5 March 2007 (2007-03-05) *
-: "RN 924789-13-9", 《STN REGISTRY》, 5 March 2007 (2007-03-05) *
-: "RN 924811-53-0", 《STN REGISTRY》, 5 March 2007 (2007-03-05) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110167558A (zh) * 2016-12-21 2019-08-23 阿泽克制药公司 三嗪三酮衍生物及其作为神经营养素受体和受体酪氨酸激酶的调节剂的用途

Also Published As

Publication number Publication date
WO2011070177A2 (en) 2011-06-16
EP2509953A2 (en) 2012-10-17
AU2010329847A1 (en) 2012-07-26
CA2783934A1 (en) 2011-06-16
CN103180297A (zh) 2013-06-26
JP2013513588A (ja) 2013-04-22
US8901129B2 (en) 2014-12-02
MX2012006580A (es) 2012-09-28
BR112012014022A2 (pt) 2017-04-04
WO2011070177A3 (en) 2011-09-01
EP2509953B1 (en) 2016-03-30
US20130030180A1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
CN104529945A (zh) 使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法
Zhang et al. Modulation of brain cation-Cl− cotransport via the SPAK kinase inhibitor ZT-1a
US6235769B1 (en) Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
RU2146520C1 (ru) Применение непептидных антагонистов рецептора тахикинина
Hodges et al. Mitochondrial pyruvate carrier inhibitors improve metabolic parameters in diet-induced obese mice
CN111655669A (zh) 治疗包括运动神经元疾病的神经紊乱的组合物和方法
US20020045566A1 (en) Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof
PT1097167E (pt) Factor de crescimento neurotrofico
JP2019501225A (ja) Ｂ細胞リンパ腫２（ｂｃｌ−２）及び関連タンパク質の阻害
TWI323660B (en) Pten inhibitor or maxi-k channels opener
Kaczorowski et al. Developing molecular pharmacology of BK channels for therapeutic benefit
CN110787158B (zh) D609在制备预防和治疗视网膜损伤性疾病药物中的应用
AU2019338236B2 (en) A GABAA receptor ligand
MX2011004789A (es) Tratamiento para la glomerulonefritis.
CN106220562B (zh) 两种喹啉环类药物的新用途
US20040191312A1 (en) 5-HT3 receptor agonists as neuroprotectors
HK40057209B (en) A gabaa receptor ligand
HK40086209B (zh) 用於治疗神经退行性疾病和线粒体疾病的组合物及其使用方法
HK40086209A (zh) 用於治疗神经退行性疾病和线粒体疾病的组合物及其使用方法
MXPA02006266A (es) Metodos para preparar formulaciones farmaceuticas..
JPWO1994007491A1 (ja) キノリジノン化合物またはその塩を含有する鎮痛剤，抗結膜炎剤または抗慢性関節リウマチ剤およびその局所投与用製剤

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150422